MOUNTAIN VIEW, Calif.,
Aug. 11, 2011 /PRNewswire/ -- MAP
Pharmaceuticals, Inc. (Nasdaq: MAPP) today announced that the
Company will participate in the 2011 Wedbush Life Sciences:
Management Access Conference on Tuesday,
August 16, at 8:35 a.m. ET in
New York.
A live webcast of the event will be available on the Investor
Relations section of MAP Pharmaceuticals' website at
http://www.mappharma.com. A replay also will be available within 24
hours for seven days following the presentation.
About MAP Pharmaceuticals
MAP Pharmaceuticals is an emerging biopharmaceutical company
focused on developing and commercializing new therapies to address
undermet patient needs in neurology. The Company is
developing LEVADEX®, an orally inhaled investigational drug for the
acute treatment of migraine. The U.S. Food and Drug Administration
has accepted for filing the New Drug Application for LEVADEX for
the potential acute treatment of migraine in adults. MAP
Pharmaceuticals has entered into a collaboration agreement with
Allergan, Inc. to co-promote LEVADEX to neurologists and pain
specialists in the U.S. and Canada. The Company also applies its
proprietary drug particle and inhalation technologies to generate
new pipeline opportunities by enhancing the therapeutic benefits of
proven drugs, while minimizing risk by capitalizing on their known
safety, efficacy and commercialization history. Additional
information about MAP Pharmaceuticals can be found at
http://www.mappharma.com.
LEVADEX has not been approved for marketing in the United States or any other country for any
indication.
|
CONTACTS:
|
|
|
Lisa Borland
|
|
|
MAP Pharmaceuticals,
Inc.
|
|
|
(650) 386-3122
|
|
|
lborland@mappharma.com
|
|
|
SOURCE MAP Pharmaceuticals, Inc.